Oncology
Video: Safety and Efficacy of JNJ-6143, a First-in-Class Oral AR-Targeted Regulated Induced Proximity Targeting Chimera at the Optimal Dose For Further Development in Patients With mCRPC/mAPMR, Including High-Risk Molecular Features
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.